More efficient mobilisation of peripheral blood stem cells with HiDAC plus AMSA plus G-CSF than with mini-ICE plus G-CSF in patients with AML
We have compared the efficacy of two PBSC mobilisation regimens, mini-ICE + filgrastim (second consolidation) and HiDAC + AMSA + filgrastim (third consolidation), in two consecutive cohorts of patients with AML CR1 receiving treatment according to a joint protocol. Group A: 18 patients, aged 41 (21-65) years, were mobilised with mini-ICE (idarubicin 8 mg/m(2) + cytarabine 800 mg/m(2) + etoposide 1